We therefore tested the same combinations of BI 853520 + /- immune costimulatory antibodies to determine whether a FAK inhibitor combined with T-cell co-stimulation could also influence a more poorly immunogenic tumor model. The gene discussed is PTK2; the disease is neoplasm.